Zobrazeno 1 - 10
of 1 026
pro vyhledávání: '"Zhi-ming Shao"'
Publikováno v:
Cancer Biology & Medicine, Vol 21, Iss 9, Pp 731-739 (2024)
Externí odkaz:
https://doaj.org/article/a2e28c6b08cc4e9ca865846640bbac33
Publikováno v:
Biomarker Research, Vol 12, Iss 1, Pp 1-19 (2024)
Abstract As one of the most common tumors in women, the pathogenesis and tumor heterogeneity of breast cancer have long been the focal point of research, with the emergence of tumor metastasis and drug resistance posing persistent clinical challenges
Externí odkaz:
https://doaj.org/article/2e9e3cb9942d46b6b7a5d88f5ea31ffe
Autor:
Chao You, Guan-Hua Su, Xu Zhang, Yi Xiao, Ren-Cheng Zheng, Shi-Yun Sun, Jia-Yin Zhou, Lu-Yi Lin, Ze-Zhou Wang, He Wang, Yan Chen, Wei-Jun Peng, Yi-Zhou Jiang, Zhi-Ming Shao, Ya-Jia Gu
Publikováno v:
npj Precision Oncology, Vol 8, Iss 1, Pp 1-13 (2024)
Abstract Radiomics offers a noninvasive avenue for predicting clinicopathological factors. However, thorough investigations into a robust breast cancer outcome-predicting model and its biological significance remain limited. This study develops a rob
Externí odkaz:
https://doaj.org/article/d87dbe7b9d9b4b60a342ae62dcb16135
Autor:
Zhi-Ming Shao, Li Cai, Shusen Wang, Xichun Hu, Kunwei Shen, Haibo Wang, Huiping Li, Jifeng Feng, Qiang Liu, Jing Cheng, Xinhong Wu, Xiaojia Wang, Hongyuan Li, Ting Luo, Jinping Liu, Khalid Amin, Khemaies Slimane, Yongping Qiao, Yongmin Liu, Zhongsheng Tong
Publikováno v:
Discover Oncology, Vol 15, Iss 1, Pp 1-12 (2024)
Abstract Background The global BOLERO-2 trial established the efficacy and safety of combination everolimus (EVE) and exemestane (EXE) in the treatment of estrogen receptor positive (ER +), HER2-, advanced breast cancer (ABC). BOLERO-5 investigated t
Externí odkaz:
https://doaj.org/article/54f05c5481a746a1854d62942484ed79
Publikováno v:
Cell Reports Medicine, Vol 5, Iss 9, Pp 101719- (2024)
Summary: Breast cancer is a common disease that causes great health concerns to women worldwide. During the diagnosis and treatment of breast cancer, medical imaging plays an essential role, but its interpretation relies on radiologists or clinical d
Externí odkaz:
https://doaj.org/article/0cba8c95b49c44dc9e92168c40e036e9
Autor:
Shen Zhao, Chao-Yang Yan, Hong Lv, Jing-Cheng Yang, Chao You, Zi-Ang Li, Ding Ma, Yi Xiao, Jia Hu, Wen-Tao Yang, Yi-Zhou Jiang, Jun Xu, Zhi-Ming Shao
Publikováno v:
Fundamental Research, Vol 4, Iss 3, Pp 678-689 (2024)
Triple-negative breast cancer (TNBC) is the most challenging breast cancer subtype. Molecular stratification and target therapy bring clinical benefit for TNBC patients, but it is difficult to implement comprehensive molecular testing in clinical pra
Externí odkaz:
https://doaj.org/article/621e0e6df23c4af781af26d51367e444
Publikováno v:
Cancer Cell International, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Extensive exploration of the molecular subtypes of triple-negative breast cancer (TNBC) is critical for advancing precision medicine. Notably, the luminal androgen receptor (LAR) subtype has attracted attention for targeted treatment combini
Externí odkaz:
https://doaj.org/article/54ec87f0885247739ab300baf78b0ca1
Publikováno v:
Signal Transduction and Targeted Therapy, Vol 9, Iss 1, Pp 1-34 (2024)
Abstract Diet, serving as a vital source of nutrients, exerts a profound influence on human health and disease progression. Recently, dietary interventions have emerged as promising adjunctive treatment strategies not only for cancer but also for neu
Externí odkaz:
https://doaj.org/article/e27aa5bacefa442a93038c8534948819
Autor:
Qiaodan Deng, Jiankun Qiang, Cuicui Liu, Jiajun Ding, Juchuanli Tu, Xueyan He, Jie Xia, Xilei Peng, Siqin Li, Xian Chen, Wei Ma, Lu Zhang, Yi‐Zhou Jiang, Zhi‐Ming Shao, Ceshi Chen, Suling Liu, Jiahui Xu, Lixing Zhang
Publikováno v:
Advanced Science, Vol 11, Iss 29, Pp n/a-n/a (2024)
Abstract Breast tumor‐initiating cells (BTICs) of triple‐negative breast cancer (TNBC) tissues actively repair DNA and are resistant to treatments including chemotherapy, radiotherapy, and targeted therapy. Herein, it is found that a previously r
Externí odkaz:
https://doaj.org/article/1e3b009041f14a21a1f006ddc2dac957
Autor:
Xuliren Wang, Weiru Chi, Yuwei Ma, Qi Zhang, Jingyan Xue, Zhi-Ming Shao, Bingqiu Xiu, Jiong Wu, Yayun Chi
Publikováno v:
Translational Oncology, Vol 46, Iss , Pp 102016- (2024)
Background: Breast cancer (BC) poses a global threat, with HER2-positive BC being a particularly hazardous subtype. Despite the promise shown by neoadjuvant therapy (NAT) in improving prognosis, resistance in HER2-positive BC persists despite emergin
Externí odkaz:
https://doaj.org/article/2514a4bfd9e3487d9296ddd490662d95